Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07136779 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
A Phase 1 study of Participants With Advanced Solid Tumor Malignancies, sponsored by VelaVigo Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 5
- Study locations
NCT07136779 is a Phase 1 study of Participants With Advanced Solid Tumor Malignancies that is actively recruiting participants, run by VelaVigo Bio. The registered enrollment target is 310 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT07136779, a Phase 1 study of Participants With Advanced Solid Tumor Malignancies, is actively recruiting participants, sponsored by VelaVigo Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC101.
Conditions Studied
Interventions
- DRUG VBC101
Study Locations (5)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Michigan
- Start Midwest - Grand Rapids
Utah
- START Mountain Region, LLC. - West Valley City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07136779
The ClinicalTrials.gov registry entry for NCT07136779 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VelaVigo Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Participants With Advanced Solid Tumor Malignancies appearing as the primary indexed condition, and to 1 intervention - of which VBC101 is the first listed.
NCT07136779 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Michigan, Utah.
Frequently Asked Questions
What is clinical trial NCT07136779 about?
NCT07136779 is a clinical study titled "First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies". This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed b...
What is the current status of trial NCT07136779?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-09-23. Estimated completion is 2028-07-01.
What conditions does trial NCT07136779 study?
This clinical trial studies the following conditions: Participants With Advanced Solid Tumor Malignancies.
What interventions are being tested in trial NCT07136779?
The interventions under investigation include: VBC101 (DRUG).
Who is sponsoring clinical trial NCT07136779?
This trial is sponsored by VelaVigo Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07136779 being conducted?
This trial has 5 study locations across Michigan, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.